1 Park Row
Leeds LS1 5AB
United Kingdom
https://www.oncimmune.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Martin John Gouldstone | CEO & Director | N/A | N/A | 1966 |
Mr. Martin Hudson | Finance Director | N/A | N/A | N/A |
Mr. Ron Kirschner | COO, General Counsel & Company Secretary | N/A | N/A | 1979 |
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Ms. Cléa Rosenfeld | Head of Investor Relations | N/A | N/A | N/A |
Mr. Maarten Brusse | Chief Commercial Officer of Asia | N/A | N/A | N/A |
Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.
Oncimmune Holdings Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.